FibroGen Rebrands to Kyntra Bio, Changes Ticker to KYNB, Signaling Strategic Pivot
FGEN has more than doubled off its 52-week low of $4.85.
Summary
FibroGen, Inc. has rebranded to Kyntra Bio, effective January 7, 2026, with its common stock trading under the new Nasdaq symbol "KYNB" from January 8, 2026, reflecting a strategic pivot towards oncology and rare disease assets.
Key Events · Corporate Governance and Compliance · FGEN
-
Company Name Change
FibroGen, Inc. officially changed its name to Kyntra Bio, Inc., effective January 7, 2026.
-
Ticker Symbol Change
The company's common stock will begin trading under the new Nasdaq symbol "KYNB" at market open on January 8, 2026.
-
Strategic Rebranding
The rebranding reflects a sharpened strategic focus on developing novel therapies in oncology and rare diseases, following a transformational year for the company.
-
Bylaws Amendment
The company's bylaws were amended to reflect the new corporate name, Kyntra Bio, Inc.
Analysis · FGEN · Life Sciences
The rebranding of FibroGen to Kyntra Bio, accompanied by a new ticker symbol, signifies a major strategic transformation for the company. This move follows a "transformational year" that included the sale of FibroGen China, debt repayment, and an extended cash runway. The new identity underscores a sharpened focus on developing novel therapies in oncology and rare diseases, particularly highlighting assets like FG-3246 (ADC) and roxadustat for myelodysplastic syndromes. For investors, this signals a clear strategic direction and a renewed commitment to specific therapeutic areas, potentially impacting future growth and valuation.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1605 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FGEN was trading at $9.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.3M. The 52-week trading range was $4.85 to $21.94. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.